Leukemia

Newer medications that displace chemotherapy aim directly at mutations in the Bruton tyrosine kinase gene and help patients with CLL live longer.

Treatment options for patients with acute myeloid leukemia are limited, especially for older patients, but a new trial looking at novel therapy combinations could change the treatment landscape.

The novel drug pairing of Venclexta and Gazyva, used for a fixed 12 months, is cost-effective compared with regimens that must be taken until disease progresses, a study finds.

Research findings show that rare mutations from donor stem cells can be passed onto patients who receive them, potentially causing health concerns.

With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.

Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.

Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.

As 2019 comes to a close, take a read through CURE®’s top stories of the year.

New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.

When one woman experienced symptoms of chronic lymphocytic leukemia, people blamed her nerves and told her to rest. Instead, she listened to her body.

Patients aged 55 and over remained in remission after receiving CC-486, according to phase 3 study findings.

Whole genome sequencing of blood and bone marrow from patients with acute myeloid leukemia and myelodysplastic syndrome has revealed previously unknown disease subtypes.

In a phase 3 clinical trial, Blincyto (blinatumomab), a type of immunotherapy, improved survival and showed fewer side effects in young patients.

Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.

New findings show that the socioeconomic status of children with AML plays a significant and alarming roll in the rate of their overall survival after diagnosis.

Baseline laboratory values for AML clinical trials are setting unnecessary restrictions for kidney function that excludes African American patients with AML when this comorbidity does not impact overall survival.